Table 2.

Hazard Ratios for Outcome among Patients with Elevated Mean Pulmonary Artery Pressure Dichotomized by Pulmonary Arterial Compliance and Stratified by Pulmonary Vascular Resistance or Pulmonary Artery Wedge Pressure

Variable	Adjusted All-Cause Mortality
	VA-CART (Discovery) Cohort (N = 37,744)		VUMC (Validation) Cohort (N = 1,514)
	HR (95% CI)	P	HR (95% CI)	P
PAC <3 ml/mm Hg	1.0	—	1.0	—
PAC ⩾3 ml/mm Hg	0.67 (0.64–0.69)	<0.001	0.58 (0.45–0.71)	<0.001
PAC <3 ml/mm Hg + PAWP ⩽15 mm Hg	1.0	—	1.0	—
PAC ⩾3 ml/mm Hg + PAWP ⩽15 mm Hg	0.59 (0.55–0.62)	<0.001	0.51 (0.38–0.69)	<0.001
PAC <3 ml/mm Hg + PAWP >15 mm Hg	1.0	—	1.0	—
PAC ⩾3 ml/mm Hg + PAWP >15 mm Hg	0.72 (0.69–0.75)	<0.001	0.65 (0.49–0.87)	0.003
PAC <3 ml/mm Hg + PVR ⩾2.2 WU	1.0	—	1.0	—
PAC ⩾3 ml/mm Hg + PVR ⩾2.2 WU	0.74 (0.70–0.78)	<0.001	0.66 (0.50–0.87)	0.004
PAC <3 ml/mm Hg + PVR <2.2 WU	1.0	—	1.0	—
PAC ⩾3 ml/mm Hg + PVR <2.2 WU	0.72 (0.69–0.76)	<0.001	0.65 (0.44–0.98)	0.039

Definition of abbreviations: CI = confidence interval; HR = hazard ratio; PAC = pulmonary arterial compliance; PAWP = pulmonary artery wedge pressure; VA-CART = Veterans Affairs Clinical Assessment, Reporting, and Tracking program; VUMC = Vanderbilt University Medical Center; WU = Wood units.

Estimates for the effect of PAC level in patients with mean pulmonary arterial pressure ⩾19 mm Hg and then further subgrouped by PAWP and pulmonary vascular resistance (PVR) are presented for the primary cohort (VA-CART) and validation cohort (VUMC). The adjustment model included the following clinical variables: categorical age, sex, race, categorical body mass index, and history of systemic hypertension, congestive heart failure, left heart failure, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease, liver cirrhosis, chronic kidney disease that included the patient receiving renal replacement therapy, portal hypertension, connective tissue disease, atrial arrhythmia, interstitial lung disease, pulmonary embolism, valvular disease, tobacco use, psychiatric disease, stroke, obstructive sleep apnea, and inpatient hospital status at the time of right heart catheterization. For the validation cohort, the following variables from the adjustment used in the primary cohort analysis were available: age, sex, race, diabetes mellitus, body mass index, coronary artery disease, valvular heart disease, chronic obstructive pulmonary disease, atrial arrhythmia, interstitial lung disease, connective tissue disease, systemic hypertension, chronic kidney disease, obstructive sleep apnea, and congestive heart failure. For both the primary and validation cohorts, the analyses with PAWP or PVR were based on the models including an interaction between PAC and PAWP or PAC and PVR. Data are presented as HR (95% CI). Reference groups are signified by an HR of 1.